NeuBase Therapeutics (STU:O7P) Long-Term Capital Lease Obligation : €4.53 Mil (As of Sep. 2023)

View and export this data going back to 2019. Start your Free Trial

What is NeuBase Therapeutics Long-Term Capital Lease Obligation?

NeuBase Therapeutics's Long-Term Capital Lease Obligation for the quarter that ended in Sep. 2023 was €4.53 Mil.

NeuBase Therapeutics's quarterly Long-Term Capital Lease Obligation declined from Mar. 2023 (€4.76 Mil) to Jun. 2023 (€4.58 Mil) and declined from Jun. 2023 (€4.58 Mil) to Sep. 2023 (€4.53 Mil).

NeuBase Therapeutics's annual Long-Term Capital Lease Obligation stayed the same from Sep. 2019 (€0.00 Mil) to Sep. 2020 (€0.00 Mil) but then increased from Sep. 2020 (€0.00 Mil) to Sep. 2021 (€5.02 Mil).

NeuBase Therapeutics Long-Term Capital Lease Obligation Historical Data

The historical data trend for NeuBase Therapeutics's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuBase Therapeutics Long-Term Capital Lease Obligation Chart

NeuBase Therapeutics Annual Data

Trend

Sep12

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

5.02

NeuBase Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															5.39	4.92	4.76	4.58	4.53

NeuBase Therapeutics (STU:O7P) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

NeuBase Therapeutics Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of NeuBase Therapeutics's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuBase Therapeutics (STU:O7P) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuBase Therapeutics Inc (STU:O7P) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

NBSE:USA O7P:Germany

Address

350 Technology Drive, Suite 421, Pittsburgh, PA, USA, 15219

Website

https://www.neubasetherapeutics.com

NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.

NeuBase Therapeutics (STU:O7P) Headlines

No Headlines